Wegovy

Page 4 of 6

A bathroom scale is surrounded by colorful pills.
Health

Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots

By Damian Garde and Bloomberg
July 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Features

Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree

By Jessica Mathews and Alena Botros
July 9, 2024
Close-up of an Ozempic pen in a greenwash style
Health

Ozempic linked to rare cases of vision loss in Harvard study

By Robert Langreth and Bloomberg
July 3, 2024
Lars Fruergaard Jorgensen, CEO of Novo Nordisk.
Health

A rare setback as Ozempic-maker Novo Nordisk takes a $820 million hit as its next wonder drug fails

By Naomi Kresge and Bloomberg
June 27, 2024
Novo Nordisk’s Wegovy may have just two years to take over China’s market for weight-loss drugs
Tech

Novo Nordisk’s Wegovy may have just two years to take over China’s market for weight-loss drugs

By
June 26, 2024
A photo of the packet for anti-obesity drug Wegovy.
Tech

India’s gray market is selling Wegovy at less than 10% of U.S. prices—even though weight-loss drugs aren’t officially available in the country

By Satviki Sanjay and Bloomberg
June 19, 2024
Baggy pants are out and smaller sizes are flying off the shelves as Wegovy changes how Americans buy clothes
Retail

Baggy pants are out and smaller sizes are flying off the shelves as Wegovy changes how Americans buy clothes

By
June 17, 2024
Ozempic and Wegovy are so hard to find that a startup invented a free tool for tracking whether the viral drugs are in stock
Health

Ozempic and Wegovy are so hard to find that a startup invented a free tool for tracking whether the viral drugs are in stock

By
May 29, 2024
‘My old doctor told me there was nothing he could do. He told me it was my fault’: Wegovy revolution sees 600% increase among young adults
Health

‘My old doctor told me there was nothing he could do. He told me it was my fault’: Wegovy revolution sees 600% increase among young adults

By Jonel Aleccia and The Associated Press
May 22, 2024
Dr. Razia Hashmi, vice president of clinical affairs, Blue Cross Blue Shield Association, speaks during Fortune’s Brainstorm Health conference in Dana Point, Calif., on Tuesday, May 21, 2024.
Health

GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study

By
May 22, 2024
Nestle CEO Mark Schneider
Retail

Nestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs

By
May 21, 2024
Dr. Patrick Carroll (right), Hims & Hers chief medical officer, speaks during Fortune’s Brainstorm Health conference in Dana Point, Calif., Monday, May 20, 2024.
Conferences

Hims & Hers’ surprise 85% Wegovy discount is latest step on a journey to make medicine less ‘paternalistic,’ exec says

By
May 21, 2024
woman shows off old oversized jeans
Health

Hims will follow its Viagra playbook and offer weight-loss drugs that are 85% cheaper than Wegovy—with Mounjaro and Zepbound in its sights next

By Madison Muller, Jessica Nix and Bloomberg
May 20, 2024
Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders
Retail

Bernie Sanders urges Danish pharma giant Novo Nordisk to lower its drug prices: ‘Help the American people’

By Christian Wienberg and Bloomberg
May 13, 2024
woman measures her waist
Health

Weaning off Ozempic slowly instead of quitting abruptly can help prevent patients from regaining weight, study says

By Ashleigh Furlong and Bloomberg
May 12, 2024

Most Popular